0.02(0.55%) Volume: 460,084 8:09PM EDT| Market Cap : 503.32 M | Enterprise Value : 203.55 M | P/E (TTM) : | P/B : 1.55 |
|---|
NAS:ACHN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ACHN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 996.92 |
ACHN's Cash-to-Debt is ranked higher than
55% of the 1056 Companies in the Global Biotechnology industry. ( Industry Median: 73.06 vs. ACHN: 996.92 ) Ranked among companies with meaningful Cash-to-Debt only. |
ACHN'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.1 Med: 131.24 Max: No Debt Current: 996.92 |
| Piotroski F-Score: 2 |
|
| Altman Z-Score: 21.96 |
|
| Beneish M-Score: -4.56 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | -597.18 |
ACHN's Operating Margin % is ranked lower than
71% of the 800 Companies in the Global Biotechnology industry. ( Industry Median: -98.02 vs. ACHN: -597.18 ) Ranked among companies with meaningful Operating Margin % only. |
ACHN'
s Operating Margin % Range Over the Past 10 Years
Min: -17954.25 Med: -432.43 Max: 11879.49 Current: -597.18 |
| Net Margin % | -568.24 |
ACHN's Net Margin % is ranked lower than
71% of the 800 Companies in the Global Biotechnology industry. ( Industry Median: -88.19 vs. ACHN: -568.24 ) Ranked among companies with meaningful Net Margin % only. |
ACHN'
s Net Margin % Range Over the Past 10 Years
Min: -17897.17 Med: -411.37 Max: 12030.34 Current: -568.24 |
| ROE % | -23.49 |
ACHN's ROE % is ranked higher than
60% of the 969 Companies in the Global Biotechnology industry. ( Industry Median: -40.23 vs. ACHN: -23.49 ) Ranked among companies with meaningful ROE % only. |
ACHN'
s ROE % Range Over the Past 10 Years
Min: -199.15 Med: -59.15 Max: -1.7 Current: -23.49 |
| ROA % | -22.64 |
ACHN's ROA % is ranked higher than
58% of the 1062 Companies in the Global Biotechnology industry. ( Industry Median: -32.55 vs. ACHN: -22.64 ) Ranked among companies with meaningful ROA % only. |
ACHN'
s ROA % Range Over the Past 10 Years
Min: -103.25 Med: -52.88 Max: -1.62 Current: -22.64 |
| ROC (Joel Greenblatt) % | -2086.87 |
ACHN's ROC (Joel Greenblatt) % is ranked lower than
72% of the 1021 Companies in the Global Biotechnology industry. ( Industry Median: -430.94 vs. ACHN: -2086.87 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
ACHN'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6041.18 Med: -2833.51 Max: -287.49 Current: -2086.87 |
| 3-Year EBITDA Growth Rate | 4.10 |
ACHN's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 722 Companies in the Global Biotechnology industry. ( Industry Median: 3.10 vs. ACHN: 4.10 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
ACHN'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0 Med: 16.2 Max: 62.2 Current: 4.1 |
| 3-Year EPS without NRI Growth Rate | 4.00 |
ACHN's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 704 Companies in the Global Biotechnology industry. ( Industry Median: 4.20 vs. ACHN: 4.00 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
ACHN'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -3.4 Med: 21.95 Max: 65.5 Current: 4 |
| Jim Simons 819,900 sh (-13.26%) Paul Tudor Jones 88,842 sh (-54.47%) |
| Jim Simons 641,300 sh (-21.78%) Paul Tudor Jones 66,703 sh (-24.92%) |
| Jim Simons 953,975 sh (+48.76%) Paul Tudor Jones 70,868 sh (+6.24%) |
| Paul Tudor Jones 245,820 sh (+246.87%) Jim Simons 2,182,467 sh (+128.78%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
Modify your Personalized List of Gurus, or
above to check out all the Gurus, or 
above for the stocks picks of all the institutional investment advisors (>4000) What is Peter Lynch Charts )| Industry: | Biotechnology » Biotechnology NAICS: 325412 SIC: 2834 | |
|---|---|---|
| Compare: | OSTO:CAMX, NAS:CDXS, TSX:TH, LSE:OXB, XKRX:141080, NAS:CNCE, XKRX:144510, HKSE:01061, NAS:RETA, NAS:CMTA, NAS:AGEN, NAS:BCRX, XKRX:083790, NAS:ACRS, NAS:NCNA, NAS:PGNX, NAS:OBSV, NAS:AKBA, ASX:MSB, SZSE:002898 » details | |
| Traded in other countries: | ADA.Germany, | |
| Headquarter Location: | USA |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PB Ratio | 1.55 |
ACHN's PB Ratio is ranked higher than
83% of the 954 Companies in the Global Biotechnology industry. ( Industry Median: 4.51 vs. ACHN: 1.55 ) Ranked among companies with meaningful PB Ratio only. |
ACHN'
s PB Ratio Range Over the Past 10 Years
Min: 0.79 Med: 3.18 Max: 12.16 Current: 1.55 |
| EV-to-EBIT | -2.39 |
ACHN's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies in the Global Biotechnology industry. ( Industry Median: 24.43 vs. ACHN: -2.39 ) Ranked among companies with meaningful EV-to-EBIT only. |
ACHN'
s EV-to-EBIT Range Over the Past 10 Years
Min: -213.5 Med: -3.7 Max: 132.9 Current: -2.39 |
| EV-to-EBITDA | -2.42 |
ACHN's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies in the Global Biotechnology industry. ( Industry Median: 21.70 vs. ACHN: -2.42 ) Ranked among companies with meaningful EV-to-EBITDA only. |
ACHN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -264.5 Med: -3.75 Max: 118.7 Current: -2.42 |
| EV-to-Revenue | 13.60 |
ACHN's EV-to-Revenue is ranked lower than
56% of the 777 Companies in the Global Biotechnology industry. ( Industry Median: 13.46 vs. ACHN: 13.60 ) Ranked among companies with meaningful EV-to-Revenue only. |
ACHN'
s EV-to-Revenue Range Over the Past 10 Years
Min: -259.4 Med: 58.1 Max: 11915.8 Current: 13.6 |
| Current Ratio | 23.59 |
ACHN's Current Ratio is ranked higher than
96% of the 1035 Companies in the Global Biotechnology industry. ( Industry Median: 4.21 vs. ACHN: 23.59 ) Ranked among companies with meaningful Current Ratio only. |
ACHN'
s Current Ratio Range Over the Past 10 Years
Min: 1.06 Med: 6.8 Max: 31.56 Current: 23.59 |
| Quick Ratio | 23.59 |
ACHN's Quick Ratio is ranked higher than
96% of the 1035 Companies in the Global Biotechnology industry. ( Industry Median: 3.92 vs. ACHN: 23.59 ) Ranked among companies with meaningful Quick Ratio only. |
ACHN'
s Quick Ratio Range Over the Past 10 Years
Min: 1.06 Med: 6.8 Max: 31.56 Current: 23.59 |
| Days Sales Outstanding | 32.12 |
ACHN's Days Sales Outstanding is ranked higher than
71% of the 656 Companies in the Global Biotechnology industry. ( Industry Median: 64.11 vs. ACHN: 32.12 ) Ranked among companies with meaningful Days Sales Outstanding only. |
ACHN'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.79 Med: 80.01 Max: 395.81 Current: 32.12 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.00 |
ACHN's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 768 Companies in the Global Biotechnology industry. ( Industry Median: -13.20 vs. ACHN: -10.00 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
ACHN'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -274.8 Med: -24.65 Max: -10 Current: -10 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Net-Cash | 1.75 |
ACHN's Price-to-Net-Cash is ranked higher than
91% of the 568 Companies in the Global Biotechnology industry. ( Industry Median: 8.85 vs. ACHN: 1.75 ) Ranked among companies with meaningful Price-to-Net-Cash only. |
ACHN'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.82 Med: 4.58 Max: 12.7 Current: 1.75 |
| Price-to-Net-Current-Asset-Value | 1.73 |
ACHN's Price-to-Net-Current-Asset-Value is ranked higher than
92% of the 695 Companies in the Global Biotechnology industry. ( Industry Median: 7.88 vs. ACHN: 1.73 ) Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only. |
ACHN'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.78 Med: 4.16 Max: 12.29 Current: 1.73 |
| Price-to-Tangible-Book | 1.55 |
ACHN's Price-to-Tangible-Book is ranked higher than
88% of the 874 Companies in the Global Biotechnology industry. ( Industry Median: 5.88 vs. ACHN: 1.55 ) Ranked among companies with meaningful Price-to-Tangible-Book only. |
ACHN'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.72 Med: 4.21 Max: 81.84 Current: 1.55 |
| Earnings Yield (Greenblatt) % | -41.80 |
ACHN's Earnings Yield (Greenblatt) % is ranked lower than
80% of the 1060 Companies in the Global Biotechnology industry. ( Industry Median: -6.86 vs. ACHN: -41.80 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
ACHN'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1513.3 Med: -15.2 Max: 2697.4 Current: -41.8 |
| Revenue (TTM) (Mil) $ | 15.00 |
|---|---|
| EPS (TTM) $ | -0.62 |
| Beta | 0.76 |
| Volatility | 62.79% |
| 52-Week Range $ | 2.58 - 5.66 |
| Shares Outstanding (Mil) | 137.89 |
| Dec18 | |
|---|---|
| Revenue (Mil $) | |
| EBIT (Mil $) | |
| EBITDA (Mil $) | |
| EPS ($) | -0.59 |
| EPS without NRI ($) | -0.59 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A |
| Dividends per Share ($) |
|
GF Chat
Excel Add-In GURUF
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP